Byondis B. V.

Driven to improve patients’ lives, Byondis is an independent biopharmaceutical research and development company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. The company is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other biopharmaceutical companies by its proprietary molecular concepts, such as its linker-drug (LD) and site-specific conjugation technologies to generate antibody-drug conjugates (ADCs).

Byondis’ broad development portfolio comprises preclinical and early- and late-stage clinical programs, including the anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985, Phase III). The company has a dedicated team of more than 350 staff including highly educated scientists and skilled technicians working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. Byondis collaborates with global biotechnology and pharmaceutical companies and national and international academic research institutions.

We are proud of the scientific expertise and the positive culture we have created within the organization. Byondis provides a fair, open and inspiring working environment, with room for ambition, entrepreneurship and new initiatives. Because we believe that success is not just what you achieve, but also how you achieve it. We believe it is important to offer students the opportunity to put their acquired knowledge into practice and to learn from each other. Often this results in a longer relationship than only an internship. For more information visit www.byondis.com .